SAN DIEGO - Capricor Therapeutics (NASDAQ: CAPR ), une entreprise de biotechnologie avec une capitalisation boursière de 546 millions $ et de solides indicateurs de liquidité selon les données d’ Inve ...

Skeletal muscle disease progression continues to slow with extended treatment (PUL v2.0) ...

Capricor Therapeutics (NASDAQ:CAPR) lost ~15% on Friday after the cell therapy developer posted long-term data from an ...

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

Panelists discuss how data from MDA 2025 demonstrate that delandistrogene moxeparvovec (gene therapy for DMD) shows ...

Muscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, causing ...

The ouster of the FDA's chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying ...

Parents of children with an incurable muscle-wasting condition have called on the Minister for Health to accelerate the ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...